Therapy Areas: Diabetes
Nutriband Inc concludes 4P Therapeutics Inc's acquisition
2 August 2018 -

Pharmaceutical company Nutriband Inc (OTCQB:NTRB) revealed on Wednesday the completion of the acquisition of 4P Therapeutics Inc for a purchase price of 250,000 shares of Nutriband's common stock and USD400,000 cash.

Based in Atlanta, 4P Therapeutics is focused on the research and development of transdermal and novel drug delivery technologies and therapeutics, added Gareth Sheridan, CEO of Nutriband.

Upon closing of the acquisition, Nutriband Inc acquires 4P's transdermal prescription pipeline in development, which consists of products to treat opioid abuse /misuse, diabetes, nausea, Infertility, Blood Pressure, Parkinson's disease, and pain relief, which are in various stages of development."

Through this acquisition of 4P, Nutriband now has a pipeline of potential transdermal products. All Nutriband products are based around the science of transdermal /topical technologies.

Login
Username:

Password:


Related Headlines

FDA Grants Breakthrough Therapy Designation for UroGen Pharma's UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

Goldfinch Bio Names GFB-887 as Clinical Development Candidate and Presents Data Demonstrating Selective Inhibition of TRPC5 for the Treatment of Genetically-driven Kidney Disease

Nuvelution Pharma Appoints Ways as Chief Medical Officer

vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer's and Diabetes at the 11thClinical Trials on Alzheimer's Disease Conference

Phase III Lonsurf Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer, According to Servier and Taiho Oncology

Cigalah Medpharm Launches Nexodyn AOS, the Tehclo-Based Wound Cleanser Developed by the Swiss Pharma company APR, in Saudi Arabia and United Arab Emirates

Symberix wins NIH grants, non-dilutive funding for lead microbiome programmes

Healogics Provides Unrestricted Educational Grant to Support an American Diabetes Association Compendium: Diagnosis and Management of Diabetic Foot Complications

Valbiotis Confirms Interest in the Study of the Intestinal Microbiota

New Guidance from ADA and EASD Recommends Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Patients with Type 2 Diabetes

Melior Pharmaceuticals Enrolls Last Subject in Phase 2b Study with Tolimidone for Type 2 Diabetes

Abbott names new chief operating officer

PharmaCyte Biotech PCT Patent Application for Cancer Therapies Published

European Medicines Accepts Drug Application for Aerie Pharmaceuticals' Rhokiinsa 

Poxel Completes Patient Enrollment for TIMES 2 Trial in Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan